2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Iron Overload, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

2886 Monoferric transferrin ameliorates ineffective erythropoiesis in MDS mice

Maayan Levy, Miguel Middle Pereira, MD2, Marina Middle Planoutene, MD3, Pinanong Na Phatthalung4, Francesca Vinchi, PhD5, Robert Fleming, MD6, Stefano Rivella, PhD7, Amit Verma, MD8, Yelena Middle Ginzburg, MD9
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Emory University, Atlanta, Georgia, United States
6 Saint Louis University, St Louis, Missouri, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
8 Albert Einstein College of Medicine, Bronx, New York, United States
9 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Myelodysplastic syndromes (MDS) are acquired iron-loading anemias.  We previously demonstrate that ferroptosis, a newly described iron-dependent lipid peroxidation-mediated form of cell death, contributes to ineffective erythropoiesis in NUP98-HOXD13 transgenic (MDS) mice and that circulating iron transporter transferrin (TF) may have therapeutic potential in iron-loading anemias.  To investigate the potential mechanism of TF’s effect on ineffective erythropoiesis, we generated mutant TF mice in which iron-binding is restricted to either the N or the C lobe and demonstrate that only monoC-blocked TF (TfC/C) mice demonstrate enhanced erythropoietin (EPO) sensitivity.  We now report results from 6-month-old MDS mice with normal TF relative to those with monoC-blocked TF (MDS;TfC/C) and monoN-blocked TF (MDS;TfN/N).

MDS mice exhibit anemia, decreased WBC count with myeloid skewing, expanded bone marrow erythroblasts, splenomegaly, and systemic iron overload.  Surprisingly, only MDS;TfN/N (but not MDS;TfC/C) mice ameliorate ineffective erythropoiesis in the bone marrow, decrease splenomegaly, increase circulating RBC count, and decrease ROS, lipid peroxidation, and apoptosis while increasing viability in bone marrow erythroblasts.  In contrast, MDS;TfC/C mice exhibit decreased hemoglobin and hematocrit and fail to improve erythroblast viability relative to MDS;Tf+/+ mice.  Interestingly, while both MDS;TfC/C and MDS;TfN/N mice exhibit decreased erythroblast Pcbp1/2, Fth1, Ncoa4, and Bclxl expression, only MDS;TfN/N erythroblasts increase Gpx4 and decrease Tfrc expression relative to MDS;Tf+/+ erythroblasts.  These results strongly support a role for monoN TF in erythroblast ferroptosis in MDS.  Furthermore, only MDS;TfN/N mice improved myeloid:lymphoid towards that in WT mice.  In addition, MDS;TfN/N restores bone mineral density to a greater extent than MDS;TfC/C mice (relative to MDS;Tf+/+ mice).  Finally, both MDS;TfC/C and MDS;TfN/N mice exhibit increased liver iron concentration as expected from prior publication. 

Taken together, we demonstrate first evidence of robustly improved ineffective erythropoiesis, erythroblast ferroptosis, and myeloid skewing in MDS mice harboring a specific mutation in monoN TF.  Work to delineate the mechanisms thereof is ongoing.

Yelena Middle Ginzburg, MD: Pharmacosmos - Research Funding; CSL Behring - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony); Mabwell - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); Ionis - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Pharmacosmos - Consultancy (Includes expert testimony)